Literature DB >> 3421531

Evaluation of a short-term saline diuresis protocol for the administration of cisplatin.

G K Ogilvie1, D R Krawiec, H B Gelberg, A R Twardock, R W Reschke, B C Richardson.   

Abstract

A study was undertaken to determine the toxic effects of cisplatin, an antineoplastic agent, on canine kidneys and bone marrow when administered during a 6-hour saline diuresis. Cisplatin (70 mg/m2 of body surface) was administered IV to 6 healthy dogs over a 20-minute period after 0.9% NaCl solution (saline) was administered IV for 4 hours at a rate of 18.3 ml/kg/hr. After cisplatin injection, saline diuresis was continued at the same rate for 2 hours. Each dog vomited within 8 hours after the drug was administered. Clinical status, weight gain, and food consumption were normal throughout the 27-day study. All measures of renal function remained unchanged and were within normal limits for 27 days after the drug was administered. Nadirs in the daily neutrophil count were observed on days 6 (3,240 +/- 404/microliters) and 15 (1,196 +/- 275/microliters). There were no important gross or histologic abnormalities referable to cisplatin administration when the dogs were necropsied at the conclusion of the study (day 27). We concluded that cisplatin can be administered safely at a dosage of 70 mg/m2 of body surface, using a short-term diuresis protocol, and that the drug induces a nadir in the neutrophil count on days 6 and 15.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3421531

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  5 in total

1.  Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Authors:  Shuang Cai; Ti Zhang; W C Forrest; Qiuhong Yang; Chad Groer; Eva Mohr; Daniel J Aires; Sandra M Axiak-Bechtel; Brian K Flesner; Carolyn J Henry; Kimberly A Selting; Deborah Tate; Jeffrey A Swarz; Jeffrey N Bryan; M Laird Forrest
Journal:  Am J Vet Res       Date:  2016-09       Impact factor: 1.156

2.  Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Authors:  D M Vail; A A Elfarra; A J Cooley; D L Panciera; E G MacEwen; S A Soergel
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration.

Authors:  Hannah Kenward; Ludovic Pelligand; Jonathan Elliott
Journal:  Exp Brain Res       Date:  2014-05-04       Impact factor: 1.972

4.  Salt suppresses IFNγ inducible chemokines through the IFNγ-JAK1-STAT1 signaling pathway in proximal tubular cells.

Authors:  Yohei Arai; Daiei Takahashi; Kenichi Asano; Masato Tanaka; Mayumi Oda; Shigeru B H Ko; Minoru S H Ko; Shintaro Mandai; Naohiro Nomura; Tatemitsu Rai; Shinichi Uchida; Eisei Sohara
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

Review 5.  Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs.

Authors:  Nicola Ambrosio; Silvia Voci; Agnese Gagliardi; Ernesto Palma; Massimo Fresta; Donato Cosco
Journal:  J Funct Biomater       Date:  2022-08-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.